Astal Laboratories Ltd has authorised the evaluation of potential acquisitions to expand its manufacturing capacity and strengthen its global market presence. The board approved initiating discussions to acquire one or more pharmaceutical manufacturing units in India that are compliant with USFDA, EU-GMP, or WHO/GMP standards. This strategic move aims to meet rising order volumes. The company's market capitalisation currently stands at Rs. 90 crore.

Strategic Expansion

The board authorised Mr. Sudheer Karna Kankanala, Whole-time Director, to evaluate opportunities and negotiate the proposed acquisition of compliant manufacturing units. This initiative is intended to bolster the company's production capabilities to address increasing demand.

Fundraising Approval

To finance these initiatives, the board authorised Mr. Balayogiswara Rao Peddinti, Chief Financial Officer, to engage with investors and financial institutions. The company plans to raise an aggregate amount of up to Rs. 300 crore through various instruments.

Authorised Instruments

The fundraising may include one or a combination of the following:

The funds will be raised via private placement or other permissible modes, subject to statutory, regulatory, and shareholder approvals. The board meeting was held on June 29, 2026, at the company's corporate office in Telangana.

Astal Laboratories Limited has re-appointed M/s V R P S & Co. Chartered Accountants as its internal auditor for the financial year 2026-27. The decision was taken by the Board of Directors at a meeting held on May 30, 2026, to ensure compliance with the Companies Act 2013 and SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

The re-appointment is effective from May 30, 2026. The firm, holding Firm Registration Number 006340S, was selected to provide a wide spectrum of services across sectors with a focus on result-oriented solutions. The auditor is committed to delivering value-added services with high standards of ethics, integrity, and quality.

Board Meeting Details

The board meeting to consider the re-appointment commenced at 05:00 P.M. and concluded at 07:20 P.M. on May 30, 2026. The disclosure was made to BSE Limited under Regulation 30 of the SEBI (LODR) Regulations, 2015, read with the SEBI Master Circular.

Key Appointment Details

The following table outlines the specific details of the re-appointment:

The company confirmed that M/s V R P S & Co. holds no relationship with any of the directors, key managerial personnel, or their relatives, ensuring independence in the audit process.